Track topics on Twitter Track topics that are important to you
Wednesday, August 23rd 2017 at 12:00pm UTC – First ACTR Combination Therapy Under Unum’s Collaboration with Seattle Genetics – – Company Plans to Initiate Patient Dosing in a Multi-center, Phase 1 Trial in Q1 2018 – CAMBRIDGE, Mass.–(BUSINESS WIRE)– Unum Therapeutics Inc., a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple …
Cet article Unum Therapeutics Announces Active Investigational New Drug (IND)
Application for ACTR087 in Combination with SEA-BCMA in Patients with
Relapsed/Refractory Multiple Myeloma est apparu en premier sur EEI-BIOTECHFINANCES.
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...